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Colostrum, the milk produced during first few days after birth, is rich in immunoglobulins,
antimicrobial peptides & growth factors. Multiple clinical trials using bovine colostrum are
ongoing but with no assessment of test product bioactivity.
Objectives
To examine variability of bioactivity between 20 commercial colostrum products, contribu-
tion of TGFβ and EGFR in mediating effects, heat sensitivity of bioactivity and changes in
bioactivity of colostrum milkings in the days following calving.
Design
In vitro bioactivity used AGS, RIE-1 and Caco-2 cell proliferation (Alamar blue) and migra-
tion (wounded monolayers) assays. Changes in colostrum bioactivity determined following
addition of TGFβ-neutralising antibody, EGFR blocker (Typhostin) and after heating (40–
60˚C, 60 min). In vivo bioassay assessed ability of colostrum gavage (2ml, 7mg/ml) to
reduce gastric damage (NSAID + restraint) in rats. Milkings from 6 cows, days 0–3 post calv-
ing were assessed for bioactivity and growth factor concentrations.
Result
Six-fold differences in pro-proliferative and migratory activity were seen comparing commer-
cial products. Comparison of most- and least-active samples from in vitro studies showed
two- to three-fold differences in ability to reduce gastric injury (86% reduction using most-
active vs 48% using least-active, p<0.01). Tyrphostin reduced pro-migratory and prolifer-
ative activity by 23% and 55%. TGFβ neutralisation reduced migratory activity by 83% but
did not affect proliferation Heating colostrum powder to 50˚C did not affect immunoactivity of
haptoglobin, EGF, TGFβ, IgG, IGF-1 or betacellulin but decreased bioactivity by >40%.
Milking studies showed high bioactivity during first and second milkings on day 0 but 77%
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Conclusion
Commercial colostrum products possess widely different bioactivity. Variation in heat expo-
sure and/or proportion of day 0 colostrum content may contribute to this. Assessment of
colostrum bioactivity has advantages to growth factor quantitation for quality control.
Introduction
Colostrum is the specific first diet of mammalian neonates and is rich in immunoglobulins,
antimicrobial peptides e.g. lactoferrin, and other bioactive molecules including growth factors
such as transforming growth factor-beta (TGFβ) and insulin-like growth factor-1 (IGF-1) [1].
In combination with the milk that is subsequently produced, it is important for the nutrition,
growth, and development of the new-born infant mammal. It also contributes to the immuno-
logical defence of the neonate and in eliminating infection and stimulating growth of the neo-
natal gastrointestinal tract [2].
Bovine (and human) colostrum contain over twenty different molecules with growth fac-
tor/pro-reparative activities [1, 3]. Although the relative concentration of individual growth
factors varies between species [4], colostrum from cows and camels have been shown to stimu-
late growth of human cell lines, confirming cross species bioactivity [1, 5]. Bovine colostrum is
a side product of the dairy industry and is easily accessible in bulk, relatively low cost to pro-
duce and, in contrast to the use of human colostrum, acceptable to most consumers. It is for
these reasons that most studies examining the value of colostrum for adult gut health issues
use bovine, rather than human colostrum.
In adults, randomised clinical trials relating to gut damage have shown beneficial effects of
oral bovine colostrum supplementation in reducing NSAID and exercise induced hyperper-
meability [6, 7] and, when given by enema, to enhance the recovery of ulcerative colitis [8].
There is also preliminary data on the potential use of colostrum for a diverse range of patholo-
gies including prevention of upper respiratory tract infections and preservation of muscle
mass [9, 10]. There are currently over 30 clinical trials underway worldwide including in the
US, UK and African continents studying the effect of bovine colostrum in both neonates for
conditions such as necrotising enterocolitis and neonatal enteropathy/stunting and in adults
for conditions such as chemotherapy induced mucositis and treatment of critically ill patients
(e.g. https://trialbulletin.com/lib/trials/term=Colostrum).
Most adult clinical trials examining the use of colostrum for gut disorders used a dose of
between 20-40g colostrum powder/day. However, as highlighted by Rathe in his review of clin-
ical trials involving colostrum [11], optimal dosage and duration of bovine colostrum supple-
mentation have not been established. It also highlights a serious confounding factor in that
investigators base dosage on the weight of the dry powder of colostrum rather than establish-
ing equivalent bioactivity, which may be influenced by breed, herd, milking times, and formu-
lation This leads Rathe to conclude that simple expressions of dosage in weight units are not
sufficiently informative and some form of bioactivity standardization needs to be undertaken
[11].
Quality control assessments of commercial colostrum are usually restricted to quoting total
protein concentration and immunoglobulin levels, neither of which give any indication as to
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pro-reparative activity. There are several potential concerns relating to consistency of colos-
trum both within and between clinical studies; 1. Producers usually ship product and recom-
mend storage at room temperature (Table 1). However, many studies are conducted in
countries or environments where high ambient temperature occur which may influence bioac-
tivity. 2. Commercial colostrum products do not specify either individual growth factor con-
centrations or, of more value, total “growth factor” bioactivity. 3. There is no strict definition
of how many days following calving the product can be considered as colostrum rather than
milk, although it is generally accepted colostrum can only be considered as such up to day 3
following calving [3]. Differences in bioactivity between producers may, therefore, exist if the
proportion of colostrum derived from different days post calving varies between suppliers.
To address these concerns relating to quality control, we therefore performed a series of
interrelated studies: 1) To determine the amount of variability of twenty commercial colos-
trum samples obtained worldwide in their ability to stimulate proliferation and migration of
intestinal cells lines. 2) Having found major variation exists, we studied the most and least
active colostrum samples using an in vivo model of gastric damage to examine if differences
seen in vitro had pathophysiological-therapeutic relevance 3) We then studied an exemplar
colostrum sample in more detail to determine the importance of the EGFR and TGFβ path-
ways in mediating its proliferative and migratory effects and whether exposing the colostrum
Table 1. Commercial colostrum sample information provided by producer.
COLOSTRUM Total stated protein (g/100
g)
Form Source Total IgG (g/
100g)
Recommended storage Lot number
Neovite lactose reduced first milk 70 Powder UK 28 Cool dry place 1805082
Neovite whole colostrum from Welsh
farms
55 Powder UK 16.5 Cool dry place SA44-01
Neovite cow’s first milk 55 Powder UK 16.5 Cool dry place 1801007
Colodan whole colostrum NS Powder Denmark 13 Cool dry place B5032-017
Bulkpowders colostrum 63.3 Powder Germany 18.99 Cool dry place NS
Biestmilch 70 Capsule Hawaii NS Store for up to 3 year at
RT
171241
Vitacost colostrum ultra NS Capsule USA 40 Room Temp 15–30˚C 3823400
Douglas Labs colostrum NS Powder New
Zealand
NS Cool dry place 15–25˚C 0153284
Immune Tree colostrum 66.7 Powder USA NS Cool dry place 9902/143
Nutracost NS Capsule USA NS NS (shipped at RT) 18010466
NOW colostrum powder NS Powder USA NS Cool dry place 3046338
Nutrablast NS Capsule USA 7 Cool dry place 279331
Sovereign Labs colostrum 60 Powder USA 5 Cool dry place 1802027
Synertek Intact Balanced First colostrum 66.7 Powder USA NS Cool dry place <25˚C 657–30
Renegade Pharmacist 66.7 Powder USA 22.11 NS (shipped at RT) 9902/221
Sterling colostrum 2070 70 Powder USA NS NS (shipped at RT) 023741
TBR labs peptide ignition colostrum 66.7 Powder USA 13 Cool dry place 03028219
Sterling colostrum 3070 70 Powder USA 25 NS (shipped at RT) 2396–9
Glanbia high fat WPC 88 Powder USA NS NS (shipped at RT) 0068701




Table shows source of colostrum samples and product data sheet information for total protein, total IgG, lot numbers and recommended storage conditions, NS = not
stated. RT = (store at) room temperature. Storage advice was either present on data sheet or through direct contact with producer. NB list of products are described in
random order and do not relate to the order of bioactivity.
https://doi.org/10.1371/journal.pone.0234719.t001
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powder to heat (as could occur during transportation or storage) affected in vitro proliferation
and migration activity and/or the immunoreactivity of various growth factors. 5) Finally, we
examined whether the date of collection of colostrum post calving had a major influence on
bioactivity and/or concentrations of a variety of growth factors present in the colostrum.
Materials and methods
Ethics
All animal experiments were approved by the Local Animals Ethics Committee (Queen Mary’s
University of London Animal Welfare Committee) and covered by project (PO13B304A) and
personal (IE9346EEF) license under the Home Office Animals Procedures Acts, 1986.
Cell lines
Caco-2 is derived from a colorectal adenocarcinoma of 72-year-old male (ATCC1HTB37TM,
ATCC, LGC standards, Teddington, UK) and exhibits tight junctions and desmosomes
between adjacent cells and grows as polarized monolayers [12]. AGS is derived from gastric
adenocarcinoma of a 54-year-old female (ATCC1 CRL-1739™, ATCC, LGC standards, Ted-
dington, UK) [13], RIE-1 is a spontaneously immortalized rat intestinal epithelial cell line (gift
from K Brown, Babraham Institute, Cambridge, UK) [14]. Cells were grown in Dulbecco’s
modified Eagle medium ((DMEM) Caco-2 and RIE-1) or RPMI 1640 medium (AGS) contain-
ing 10% fetal calf serum at 37˚C in 5% CO2. All cells are routinely mycoplasma tested.
Study series 1
A. Variation in in vitro bioactivity of commercial products
Background to protocol. These studies examined variation in bioactivity between differ-
ent commercial samples using in vitro models of the early stages of gut repair i.e. cell migration
and proliferation.
Commercial colostrum samples. 20 commercial bovine colostrum samples promoted as
health food supplements were purchased via the internet. Source countries of these samples
included mainland USA, Hawaii, Denmark, Germany, UK and New Zealand. All products
stated that they are 100% colostrum (Table 1).
Preparation of samples. Samples that were already in powdered form or collected from
capsules were dissolved in phosphate buffered saline (PBS, Sigma) to a concentration of 10
mg/ml with vortexing. Subsequent dilutions were made in serum free medium (SFM) for cell
migration and cell proliferation assays. For immunoassays, samples were diluted in relevant
assay buffer. For in vivo experiments, colostrum samples for gavage were dissolved in sterile
water. Protein assays were performed using a standard Bicinchoninic Acid (BCA) assay
(Sigma, Poole, Dorset, UK).
Proliferation assay methods. Cell proliferation assays were performed as previously
described [15], utilising Alamar blue (Invitrogen, Paisley, UK), as per manufacturer’s instruc-
tions. Briefly, AGS cells, Caco-2 cells, or RIE-1 cells were seeded at 2000 cells/well, grown in
medium and 10% FCS in 96 well plates overnight (20 hours). Cells then had the medium
removed and were washed twice using 200 μl of SFM using a multichannel pipette (Anachem,
Beaumont Leys, Leicester, UK) and incubated in colostrum preparations, or SFM alone as a
negative control. In addition, as in our previous studies using this method [16], additional
wells had a standard dose of EGF (1 μg/ml in SFM) added as a positive control where the rise
in proliferation (increase in A570 above baseline) caused by the EGF is defined as 100%. This
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provides the potential to compare relative effects across different assay days where the absolute
values will vary. All results are expressed as mean +/- SEM for quadruplicate wells.
Pilot studies using (0.5–4 mg powder/ml) determined the optimum concentration for sub-
sequent in vitro experiments to be 1 mg powder/ml. The dose-response curve showed that
higher concentrations did not stimulate proliferation further and at a concentration of 4 mg/
ml, values decreased due to the toxic effect of the colostrum causing the cells to become
detached (S1 Fig).
All 20 commercial colostrum products were assessed for pro-proliferative activity in the
three cell lines using 1 mg powder weight/ml. In addition, we compared all 20 samples in their
ability to stimulate proliferation of AGS cells when the amount of colostrum sample added
was standardised according to its protein content such that each well received 0.6 mg total
colostrum protein/ml (rather than 1 mg/ml of colostrum powder weight).
Cell migration assay methods. Cell migration assays were performed using AGS, Caco-2
and RIE-1 cells using our previously published methods [17]. Briefly, confluent monolayers were
grown in 24 well plates in 10% serum containing medium. Standard wounds were inflicted by
scraping a pipette tip across the monolayer and medium removed. Cells were washed immediately
with 2 ml of serum-free medium to remove released soluble factors. Cells were then incubated in
SFM alone (negative control), or SFM containing the colostrum samples. In addition, as in our
previous studies [16] further wells had EGF (1 μg/ml in SFM) added as a positive control where
the amount of movement caused by EGF was defined as 100%, providing the potential to compare
relative effects across different assay days where the absolute values will vary.
Serial photomicrographs were taken using an inverted microscope (Nikon TS100; Tokyo,
Japan) and a Nikon Coolpix 800 digital camera with 125-fold magnification [18]. Twenty mea-
surements per field were performed by placing a transparent grid over the photograph and
measuring the distance moved from the original wound line. The exact width of the wound is
therefore not relevant as it is the movement of the wound edge from time zero that is assessed.
As for the proliferation assays, all 20 commercial colostrum products were assessed for pro-
migratory activity in all three cell lines using 1 mg powder weight/ml and additional studies
performed comparing all 20 samples in their ability to stimulate migration of AGS cells when
the amount of colostrum sample added was standardised according to its protein content such
that each well received 0.6 mg total colostrum protein/ml (rather than 1 mg/ml of colostrum
powder weight). All results are expressed as mean +/- SEM for triplicate wells.
B. Pathophysiological relevance of in vitro differences in bioactivity
Background to protocol. To examine whether differences in in vitro bioactivity found in
study 1A had pathophysiological relevance, we used a rat gastric damage model to compare
the samples with the most- and least-stimulatory bioactivity (colostrum sample 1 or 20 from
Fig 1A) in their ability to reduce gastric damage.
Rat gastric damaging model. The ability of colostrum to prevent gastric damage in rats
stressed by indomethacin and restraint was assessed using our previously validated model [6].
Gastric damage is induced through the combination of the toxic NSAID effects of the indo-
methacin which is enhanced by the short-term (3 hour) stress of restraint [19]. The indometh-
acin is not given to provide analgesia and it is of note that opiate analgesia cannot be given as it
reduces acid secretion preventing injury occurring [19].
Briefly, Sprague Dawley rats (all males, N = 8 per group, 200–225 g) received 2 ml total
gavage volume containing either the most-active or least-active performing colostrum from
the in vitro studies (sample 1 or sample 20 from Fig 1A) at 7 mg/ml, wt/vol. This dose of colos-
trum was chosen based on our previous studies examining effects of a colostrum product in
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this model [6]. An additional group received the same gavage volume containing BSA (7 mg/
ml) as a negative control. Mean body weight for each of the 3 groups were control 215.1 +/-,
4.4 g animals receiving most active colostrum 215.4 +/- 3.5 g, animals receiving least active
colostrum 215.0 +/- 2.1 g, no significant difference between groups.
All gavage solutions also contained 2% hydroxymethylpropylcellulose (Sigma) to reduce
the rate of gastric emptying. Thirty minutes after gavage, all rats received indomethacin (20
mg/kg, subcutaneously, Sigma) and were placed in Bollman type restraint cages. Animals were
killed three hours later using a Schedule 1 method (inhalation of carbon dioxide gas) and their
stomachs removed and inflated with 4 ml of 10% formalin (Sigma). The stomachs were ran-
domly coded and macroscopic and microscopic assessment of injury assessed in a blinded
fashion. Macroscopic injury was assessed using a dissecting microscope (×10) with the aid of a
reference square grid and reported as the total area of ulceration per stomach (mm2/stomach).
The stomachs were then embedded in wax and the depth of damage assessed microscopically
as previously described [6]. Briefly, microscopic injury was graded with a score from 0 to 4
where: 0 = no damage,1 = one small erosion (>0.5 mm), 2 = two small or one large erosion
(< 0.5 mm), 3 = two or more large erosions, and 4 = any area of ulceration extending to the
muscularis mucosa.
Fig 1. Variation in pro-proliferative and pro-migratory bioactivity of commercial colostrum samples.
https://doi.org/10.1371/journal.pone.0234719.g001
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C. Relevance of EGFR, TGFβ and heat stability on proliferative and
migratory activity
Background to studies. We examined the importance of TGFβ and EGFR pathways in
mediating in vitro bioactivity and the effect of short-term heat exposure on bioactivity and
immunoreactivity. Given the large number of measurements to be undertaken, we identified a
typical colostrum sample from study Series 1 (sample 9), which ranked at the midpoint of the
relative bioactivity of the 20 samples for these more detailed analyses.
Immunoneutralization studies. Colostrum sample 9 was added to wells at 1 mg powder/
ml in the presence and absence of an EGFR blocker (Tyrphostin, 100 nM, Sigma) to examine
the EGFR pathway or a TGFβ (100μg/ml) neutralising antibody (antibodies-online.com,
Aachen, Germany) to examine the importance of the TGFβ pathway and assessed for pro-pro-
liferative and migratory activity.
Heat stability studies. Four 5g aliquots of dry powder colostrum sample 9 were placed
into falcon tubes. Three of these were heated for 1 h at 40, 50 or 60˚C by placing in a laboratory
oven under continuous rotation and the fourth kept at laboratory room temperature (21˚C,
control) throughout. Samples were removed from oven and left overnight to return to room
temperature. Samples were subsequently diluted to 1 mg powder/ml and analysed using prolif-
eration and migration assays and for growth factor immunoactivity. To show that protein con-
centration had not been altered by the heating, protein concentration of samples was
determined before and after using BCA assay.
Study series 2
Variation in bioactivity and growth factor immunoactivity in colostrum
samples during days 0–3 after calving
Collection, processing, and assays of milkings. Colostrum samples were collected
from 6 multiparous Holstein cows during January 2019. Cows were sampled at first and sec-
ond colostrum milking and daily for the following 3 days. Colostrum was harvested into indi-
vidual milking buckets, agitated, and subsampled with a stainless-steel dipper into 20 mL
plastic vials and frozen within 30 min after collection. Samples were kept frozen at -20˚C until
freeze drying by APS Biogroup (Phoenix, AZ). All animals provided specimens for each time
point.
Samples were subsequently analysed for pro-proliferative and pro-migratory effects and
levels of IgG and growth factors determined using commercial ELISA kits according to manu-
facturer’s instructions. Measured components comprised bovine EGF, bovine TGFβ, bovine
haptoglobin, and bovine betacellulin (from antibodies-online.com, Aachen, Germany), bovine
IgG and IGF-1 from R&D systems (Abingdon, UK) and bovine betacellulin from Abcam
(Cambridge, UK).
Statistics
All results are expressed as mean ± SEM. Statistics were performed using Graphpad Prism 8
version 8.3.1. Test for normality of data using Shapiro Wilks test showed equal variances
between groups. Commercial samples studies were assessed using one-way analysis of variance
(ANOVA). Comparisons between treatments was performed using a Tukey’s multiple com-
parison test. For cell migration and proliferation assays, N = 3 or 4 wells per treatment were
used to generate a power of 0.76 and 0.8, respectively, for an effect of change of 50% and a sig-
nificance of p<0.05. For rat gastric damaging model, N = 8 per group were used to generate a
power of 0.83 for an effect of change in damage of 25% and a significance of p<0.05. For study
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series 2, a 2-way ANOVA was used with cow and time as factors. Where a significant effect
was seen (p<0.05) in the ANOVAs, individual comparisons between groups were performed
based on the group means, residual, and degrees of freedom obtained from the ANOVA, a
method equivalent to repeated measures analysis.
Results
Study series 1
A. Variation in bioactivity of commercial products. A wide range of pro-proliferative
(Fig 1A) and pro-migratory (Fig 1C) activity was seen, with an approximate 6-fold difference
between the most active and least active samples when tested on a mg powder per ml basis.
Relative bioactivity across the two assays were generally consistent with the most active and
least active samples being similar in both assays. Similar results were seen when samples were
tested using a standardised mg colostrum protein/ml basis (Fig 1B and 1D) rather than a stan-
dardised colostrum powder weight/ml basis.
AGS cells were incubated in 1 mg powder/ml (A&C) or a standardised amount of total
colostrum protein, 0.6 mg protein/ml (B&D) of 20 different commercial colostrum samples
for 24h. Changes in proliferation assessed using (Alamar Blue) (A&B) and movement of lead-
ing edge of wounded monolayers (C&D) determined. Results expressed as % response com-
pared to effect caused by adding 1μg/ml EGF (positive control, defined as 100%). Colostrum
sample numbers and colouring in A-D remain consistent taken from Fig 1A. SFM shows result
of serum free medium alone (baseline control). Results expressed as means +/- SEM of 4
wells (proliferation assays) or 3 wells (migration assays). Results of one-way ANOVA showed
significant differences between colostrum samples. Labelled means without a common letter
are significantly different, P<0.05. Similar results seen using Caco-2 or RIE-1 cells (S2 Fig and
S3 Fig).
B. Pathophysiological relevance of in vitro differences in bioactivity. All animals com-
pleted the study protocol. Most active (sample 1) and least active (sample 20) colostrum sam-
ples showed about a two-fold difference in the degree of reduction in macroscopic injury (86%
reduction in macroscopic injury using most active sample vs 48% using least active, p<0.01,
Fig 2A). Similar results were seen using microscopic scoring with a three- to four-fold differ-
ence in protective ability (74% reduction in injury using most active vs 15% using least active
sample, p<0.01, Fig 2B). Animals receiving most active colostrum showed virtually normal
gastric histology (Fig 2C), whereas animals receiving least active colostrum continued to have
multiple erosions present (Fig 2D).
C. Relevance of EGFR, TGFβ and heat stability on proliferative and migratory
activity. Immunoneutralization studies. Pro-proliferative activity of the colostrum sample
9 was reduced by 55% in the presence of the EGFR blocker Tyrphostin (p<0.01). The addition
of TGFβ neutralising antibody did not affect the pro-proliferative effect of the colostrum
(Table 2).
Pro-migratory activity of the colostrum sample was reduced by 23% in the presence of the
EGFR blocker Tyrophostin (p<0.01). Similarly, the addition of TGFβ neutralising antibody
caused pro-migratory activity of colostrum to fall by 83% (p<0.01, Table 2).
Heat stability studies. Subjecting colostrum powder to heat at 50–60˚C for 1h caused a pro-
gressive fall in bioactivity in both proliferation and migration (Fig 3). In contrast, there was no
significant change in bovine EGF, bovine TGFβ, bovine haptoglobin, bovine betacellulin,
bovine IGF-1 or bovine IgG immunoreactivity following heating (Fig 3). Total protein concen-
tration of sample was unaffected by dry heating.
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Fig 2. Effect of colostrum samples on NSAID-induced gastric injury. Rats received 2ml oral gavage of control (BSA), or the most active or least active
colostrum samples determined from Fig 1A (colostrum samples numbered 1 and 20), 30 minutes prior to receiving indomethacin (20mg/kg, sc), and 3h of
restraint. Amount of macroscopic (A) and microscopic (B) damage was subsequently assessed. Microscopic scoring scheme described in [3]. Stomachs from
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Study series 2
Variation in bioactivity and growth factor immunoactivity in colostrum
samples during days 0–3 after calving
When the colostrum samples were compared on a powder weight basis, pro-proliferative activ-
ity of colostrum remained high during first and second milkings on day 0. Days two and three
showed a progressive drop off in activity such that about two thirds of the activity was lost by
day 3 (Fig 4A). Protein concentrations of the samples progressively fell from day 0 to day 3
(Fig 4C). When the same colostrum samples were compared by standardising based on protein
content, such that each well received the same amount of total colostrum protein, rather than
total weight of the powder, there was no significant difference in pro-proliferative activity
across the three days (Fig 4B). Similar results were seen when following pro-migratory activity
(S4 Fig).
Immunoassays of growth factors showed the following absolute value results from the ini-
tial (Day 0–1) samples; EGF (16.9 +/- 0.7 ng/mg powder), TGFβ (25.7 +/- 4.4 pg/mg powder),
haptoglobin (11.1 +/- 0.8 μg/mg powder), betacellulin (405.0 +/- 2.6 ng/mg powder), IGF-1
(438.3 +/- 10.0 ng/mg powder) and IgG (15.36 +/- 0.3 μg/mg powder). To follow changes in
levels across all growth factors with very different initial concentrations, results are expressed
as percentage change compared to Day 0–1 (Fig 4D). This showed haptoglobin, EGF, TGFβ,
IgG, IGF-1 levels paralleled falls in proliferative activity although betacellulin levels remained
stable for the test period.
Discussion
Using a combination of in vitro and in vivo models, we showed marked variability in biologi-
cal activity of colostrum using assays relevant for gastrointestinal integrity and repair. Some of
these differences may relate to the date of colostrum collection following calving, or to trans-
portation or storage conditions of powdered form.
Whatever the initiating injury to the gastrointestinal tract, repair begins within the first few
hours by surviving cells at the edge of the wound migrating over the denuded area to re-estab-
lish epithelial continuity, a process termed restitution. This is followed by increased
animals that received NSAID + most active colostrum had essentially normal histology (C) whereas animals receiving NSAID + least active colostrum
continued to show multiple erosions (D). Results expressed as mean +/- SEM of 8 animals per group. �� signifies p< 0.01 vs control and $ $ signifies p< 0.01
of best sample vs worst.
https://doi.org/10.1371/journal.pone.0234719.g002
Table 2. Importance of EGFR and TGFβ on proliferative and migratory activity of colostrum.
SFM alone Colostrum
alone
Colostrum + EGFR blocker
(Tyrphostin)
Colostrum + TGFβ neutralising
antibody




123.3 +/- 8.5 78.7 +/- 2.4�� 118.2 +/- 5.5 (NS, p = 0.214))




69.3 +/- 0.2 59.6 +/- 1.3�� 34.9 +/- 0.2��
AGS cells were incubated in 1 mg powder/ml colostrum +/- EGFR blocker (Tyrphostin, 100 nM) or a TGFβ (100 μg/ml) neutralising antibody for 24h. Changes in
proliferation assessed using (Alamar Blue) and movement of leading edge of wounded monolayers determined. Results expressed as % response compared to effect
caused by adding 1μg/ml EGF (positive control, defined as 100%). SFM shows result of serum free medium alone (baseline control). Results expressed as means +/- SEM
of 4 wells (proliferation assays) or 3 wells (migration assays).
�� signifies p<0.01 vs colostrum alone. NS- no significant difference vs colostrum alone
https://doi.org/10.1371/journal.pone.0234719.t002
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proliferation which begins about 24 h following injury and a final remodelling period which
occurs over many weeks or months [20]. The proliferation and migration assays used in the cur-
rent studies have been used by our and other groups previously to compare relative bioactivity of
nutritional products (e.g. Ref 16). Consistent results were seen in all three cell lines from stomach,
small and large intestinal origin. Six-fold differences in bioactivity were seen when samples were
compared on a powder weight basis, as would be taken by the consumer/patient and also when
samples were standardised so that the cells received the same amount of total colostrum protein,
rather than same amount of powder weight. This excludes the possibility that variation in total
colostrum protein content between products was the cause of these differences.
We used a well-established rat indomethacin-restraint gastric damage model to examine
whether the differences seen in in vitro bioactivity could have pathophysiological relevance. It
has been used by us and others previously to compare relative protective activity between
nutritional compounds with therapeutic potential [16]. This model also seemed particularly
Fig 3. Effect of heating on colostral proliferative and migratory activity and growth factor immunoreactivity. Three
5g samples of sample 9 (from Fig 1A) were heated for 1 h at 40, 50 or 60˚C and the fourth kept at laboratory room
temperature (21˚C, control) throughout. Samples were diluted to 1 mg powder/ml and effects on proliferation (△), cell
migration (▽) and growth factor immunoactivity were then determined. In contrast to proliferation and migration results,
growth factor immunoreactivity did not change; bovine EGF (▲), bovine TGFβ (▼), bovine haptoglobin (●), bovine
betacellulin (◼), and bovine IgG (◯), IGF-1 (☐). Results expressed as % of unheated control, mean +/- SEM of 3
(restitution) or 4 (proliferation and immunoassays) wells per group. �� signifies p< 0.01 vs equivalent bioactivity of
unheated (laboratory room temperature) colostrum.
https://doi.org/10.1371/journal.pone.0234719.g003
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relevant as colostrum is currently marketed for “gastric health”. In keeping with the results
from the in vitro studies, the most active colostrum product was three times more effective in
reducing gastric injury compared to the worst performing sample from the in vitro study. This
finding of concordance between the efficacy in the in vitro proliferation and migration assays
and the in vivo model supports the pathophysiological relevance and use of in vitro assays for
colostrum quality control and product development purposes.
Indomethacin causes damage to the gastrointestinal tract by several mechanisms including
reduction of mucosal prostaglandin levels, reduction of mucosal blood flow, stimulating
Fig 4. Change in colostral biological and immunoactivity post calving using AGS cells. Colostrum was collected at first and second milking and daily for the
following 3 days from 6 cows post calving. Samples were converted into powdered form using freeze drying and subsequently analysed for pro-proliferative activity
(AGS cells) using Alamar Blue and growth factor concentrations using commercial ELISA kits. A) Proliferative results comparing samples using 1 mg powder/ml. B)
Proliferative results comparing samples standardised so that each well received 0.4 mg protein/ml. Results expressed as % response compared to effect caused by adding
1μg/ml EGF (positive control, defined as 100%). SFM shows result of serum free medium alone. Results expressed as mean +/- SEM of 6 animals per time point, with
each sample measured in quadruplicate. C. Change in total protein concentration in the dried colostrum samples over the four-day period. D. Growth factor
immunoreactivity expressed as % of Day 0–1 sample (absolute values of day 0–1 given in main text); EGF (π), TGFβ (θ), bovine haptoglobin (•), bovine betacellulin (0),
IGF-1 (�) and IgG (�). Results expressed as mean +/- SEM of 6 animals per time point, with each sample measured in triplicate. For A-D, �� signifies p<0.01 vs Day 0–1
value.
https://doi.org/10.1371/journal.pone.0234719.g004
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neutrophil activation, and possibly also stimulating apoptosis [21]. It is likely that many of
these mechanisms will be influenced by the numerous growth factors present in the colostrum
preparation. The current studies involving Tyrphostin and TGFβ immunoneutralization, in
combination with previous experiments involving size exclusion studies of bovine colostrum
[22], suggest that EGF, TGFβ1 and bovine colostrum derived growth factor are probably all
involved in the protective effect. However, the EGFR has multiple ligands [23] and growth fac-
tors can act synergistically when added together [24]. In addition, growth factors, such as EGF
and TGFα, and cytokines such as IL-1β and IFN-γ stimulate migration through increasing
local production of TGFβ1 [25]. The inhibitory actions of the TGFβ blocking antibody may,
therefore, not solely be due to the neutralisation of TGFβ present within the colostrum.
Following collection, colostrum is usually frozen and stored at the farm and transported in
bulk to a processing plant where it is defrosted, pasteurised, and converted to powder form
using processes such as spray drying. The end consumer/researcher therefore normally pur-
chases colostrum for personal use or for clinical trials in powdered form. No special provision
is given for transportation, and product is delivered via standard freight services with recom-
mended storage conditions usually stated as “store at room temperature”. The current studies
demonstrate that even a relatively short exposure of the powdered colostrum to temperature
above 40˚C has a profound effect on its bioactivity. This finding has direct relevance to the
transportation and storage of product for clinical studies being undertaken, especially in hot
climates. Importantly, this decrease in bioactivity due to heating was not paralleled by a falloff
in immunoreactivity of multiple growth factors present within the colostrum, even at the high-
est temperature. We therefore consider that bioassays are the optimal method to confirm
maintenance of bioactivity for clinical use. Differences in pasteurisation techniques between
manufacturers may also be relevant in explaining the variation in bioactivity between commer-
cial colostrum samples as heating to>60˚C is performed, however, it is important to note that
he temperature sensitivity of bioactivity may be different when colostrum is in its liquid form
rather than in its final powdered form. Additional studies would be required to examine this
but would be hampered by the fact that the details of the colostrum production (including pas-
teurisation) are proprietary information and not readily disclosed by the manufacturers.
Our studies examining changes in the milkings immediately following calving showed a rapid
drop off in both bioactivity and growth factor concentrations (except for betacellulin) by day 3.
These results support previous reports describing similar reductions in total protein, IgG and
cytokines such as IL-1β, IL-6 and TNF-α in colostrum over the same period [3, 26]. When the
same milkings were assessed for bioactivity using standardised protein content, rather than pow-
der weight, no difference in bioactivity between day zero and day 3 were seen. These results sug-
gest that variation in the proportion of day 0 colostrum used in the commercial products can only
be a minor contributor to explaining differences between the commercial products, as differences
in bioactivity between the colostrum products remained even when corrected for protein content.
The commercial colostrum samples used for these studies are currently considered food
products for marketing legislation purposes. However, as they contain potent biologically
active molecules, have been shown to be biologically active in a variety of in vivo models of
injury and are being used for medicinal purposes, they should also be considered as nutraceuti-
cals (a term combining nutrition and pharmaceutical). Legislation requires tight quality con-
trol on conventional medicines where major differences in bioactivity per standard weight of
product due to processing or other factors would be considered unacceptable. To interpret
results from clinical trials accurately, especially when comparing results from different investi-
gators, the colostrum being used needs to be appropriately quality controlled. Prior to under-
taking a clinical trial, we suggest the bioactivity of the colostrum is checked, as relying on
weight of powder, protein content, or growth factor immunoassay is ineffective. In addition,
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researchers need to ensure that the test colostrum product is not exposed to even transient
temperature rises above 40˚C.
Supporting information
S1 Fig. Effect of colostrum on proliferation: Pilot dose response. AGS cells were incubated
in the presence various concentrations of powdered colostrum (0.125–4 mg powder/ml). Cells
grown in SFM alone (baseline control) shown as zero concentration of colostrum. Changes in
proliferation were assessed by adding Alamar blue and measuring changes in absorbance at
570 nm. Results shown as means +/- SEM of 4 wells per sample and presented as % response
compared to effect caused by 1μg/ml EGF (positive control, defined as 100%). �� signifies
p<0.01 vs SFM alone.
(TIFF)
S2 Fig. Variation in bioactivity of commercial products using RIE-1 cells. RIE-1 cells were
incubated in 1 mg powder/ml of 20 different commercial colostrum samples for 24h. Changes
in proliferation assessed using (Alamar Blue) (A) and movement of leading edge of wounded
monolayers (B) determined. Colostrum sample numbers and colouring remain consistent
taken from Fig 1A. Results expressed as % response compared to effect caused by adding 1μg/
ml EGF (positive control, defined as 100%). SFM shows result of serum free medium alone.
Results expressed as means +/- SEM of 4 wells (proliferation assays) or 3 wells (migration
assays). Results of one-way ANOVA showed significant differences between colostrum sam-
ples. Labelled means without a common letter are significantly different, P<0.05.
(TIFF)
S3 Fig. Variation in bioactivity of commercial products using Caco-2 cells. Caco-2 cells
were incubated in 1 mg powder/ml of 20 different commercial colostrum samples for 24h.
Changes in proliferation assessed using (Alamar Blue) (A) and movement of leading edge of
wounded monolayers (B) determined. Colostrum sample numbers and colouring remain con-
sistent taken from Fig 1A. Results expressed as % response compared to effect caused by add-
ing 1μg/ml EGF (positive control, defined as 100%). SFM shows result of serum free medium
alone. Results expressed as means +/- SEM of 4 wells (proliferation assays) or 3 wells (migra-
tion assays). Results of one-way ANOVA showed significant differences between colostrum
samples. Labelled means without a common letter are significantly different, P<0.05.
(TIFF)
S4 Fig. Change in colostral pro-migratory activity post calving using AGS cells. Colostrum
was collected at first and second milking and daily for the following 3 days from 6 cows post
calving. Samples were then analysed for pro-migratory activity (AGS cells). A) Migratory
results comparing samples using 1 mg powder/ml. B) Migratory results comparing samples
standardised so that each well received 0.4 mg protein/ml. Results expressed as % response
compared to effect caused by adding 1μg/ml EGF (positive control, defined as 100%). SFM
shows result of serum free medium alone. Results expressed as mean +/- SEM of 6 animals per
time point, with each sample measured in triplicate. �� signifies p<0.01 vs Day 0–1 value.
(TIFF)
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